论文部分内容阅读
目的:观察痰热清注射液联合利巴韦林治疗小儿手足口病的临床疗效。方法:将符合纳入标准的60例手足口病患儿按区组随机分成治疗组30例及对照组30例,2组均采用退热、补液等对症治疗,治疗组静脉给予痰热清注射液0.3～0.5mL·kg-1·d-1加入5%或10%葡萄糖液100～250 mL静脉滴注,最大不超过10 mL,利巴韦林注射液10～15 mL·kg-1·d-1加入5%或10%葡萄糖100～250 mL静脉点滴,每日2次,并根据情况纠正水电解质紊乱,连用5 d。对照组给予静脉点滴利巴韦林10～15 mL·kg-1·d-1,每日2次,连用5 d。2组治疗5 d为1个疗程,观察2组患者体温下降,皮疹消退情况。结果:从发热、皮疹消退情况观察,统计资料显示,治疗组与对照组比较有显著性差异(P<0.05)。结论:痰热清注射液联合利巴韦林注射液治疗小儿手足口病普通型病例具有明显抗病毒、退热及改善症状作用,值得推广应用。
Objective: To observe the clinical efficacy of Tanreqing injection combined with ribavirin in the treatment of hand-foot-mouth disease in children. Methods: 60 cases of hand, foot and mouth disease patients who met the inclusion criteria were randomly divided into treatment group (30 cases) and control group (30 cases). Both groups were treated with antipyretic and fluid replacement therapy. The treatment group received intravenous injection of Tanreqing Injection 0.3 ~ 0.5mL · kg-1 · d-1 added 5% or 10% glucose solution 100 ~ 250mL intravenous drip, the maximum does not exceed 10mL, Ribavirin injection 10 ~ 15mL · kg-1 · d -1 add 5% or 10% glucose 100 ~ 250 mL intravenously, 2 times a day, and according to the situation to correct water and electrolyte disorders, once every 5 d. The control group received intravenous infusion of ribavirin 10 ~ 15 mL · kg-1 · d-1 twice daily for 5 days. 2 groups of 5 days for a course of treatment, observed in 2 patients with decreased body temperature, rash subsided. Results: From the fever, rash subsided observation, statistical data show that the treatment group and the control group were significantly different (P <0.05). Conclusion: Tanreqing injection combined with ribavirin injection in children with common type of hand, foot and mouth disease has obvious anti-virus, antipyretic and improvement of symptoms, which is worth popularizing and applying.